BioPorto Diagnostics AS - Product Pipeline Analysis, 2023 Update

Summary


BioPorto Diagnostics AS (BioPorto Diagnostics), formerly AntibodyShop AS is an in-vitro diagnostics company that manufactures and markets antibodies and antibody based products. It's products include matched reagent set, immunoassays, antigens, antibodies, controls calibrators and matched antibody pairs, among others. It offers cell biology products, NGAL rapid ELISA Kit and Gc-globulin action free ELISA Kit, among others. BioPorto dDiagnostics offers various antibodies with specificity within medical specialties such as obesity, diabetes and primary immune deficiency. The company provides NGAL Test a diagnostic acute kidney injury biomarker which is measured in both human urine and plasma. It markets its products through sales channels and partners. BioPorto Diagnostics is headquartered in Copenhagen city, Copenhagen, Denmark.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company BioPorto Diagnostics AS
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company


BioPorto Diagnostics AS Company Overview
BioPorto Diagnostics AS Company Snapshot
BioPorto Diagnostics AS Pipeline Products and Ongoing Clinical Trials Overview
BioPorto Diagnostics AS – Pipeline Analysis Overview
BioPorto Diagnostics AS - Key Facts
BioPorto Diagnostics AS - Major Products and Services
BioPorto Diagnostics AS Pipeline Products by Development Stage
BioPorto Diagnostics AS Ongoing Clinical Trials by Trial Status
BioPorto Diagnostics AS Pipeline Products Overview
gRAD Test - COVID-19 IgG/IgM
gRAD Test - COVID-19 IgG/IgM Product Overview
gRAD Test - Sepsis
gRAD Test - Sepsis Product Overview
NGAL (Neutrophil Gelatinase-Associated Lipocalin) Test - Kidney Injury
NGAL (Neutrophil Gelatinase-Associated Lipocalin) Test - Kidney Injury Product Overview
Point of Care Test - SARS-CoV-2
Point of Care Test - SARS-CoV-2 Product Overview
ProNephro AKI (NGAL) - Pediatrics
ProNephro AKI (NGAL) - Pediatrics Product Overview
ProNephro AKI (NGAL) - Pediatrics Clinical Trial
The NGAL Test - Adults
The NGAL Test - Adults Product Overview
BioPorto Diagnostics AS - Key Competitors
BioPorto Diagnostics AS - Key Employees
BioPorto Diagnostics AS - Locations And Subsidiaries
Head Office
Recent Developments
BioPorto Diagnostics AS, Recent Developments
Dec 07, 2023: BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years
Nov 01, 2023: BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference
Sep 11, 2023: BioPorto Provides Update on NGAL Test Regulatory Pathway
Jun 29, 2023: Bioporto Announces Submission of Response to FDA Additional Information Letter
Nov 11, 2022: BioPorto submits De Novo application to FDA for NGAL test
Oct 27, 2022: BioPorto exhibiting NGAL biomarker at ASN kidney week – antibodies, ELISA kits, and clinical chemistry assays for early drug development and clinical research
Jun 28, 2022: BioPorto achieves targeted enrollment in clinical study supporting FDA De Novo Submission for The NGAL Test in the U.S.
May 11, 2022: Strong performance of the NGAL Test drives revenue growth
Dec 31, 2021: Pipeline update on gRAD Tests
Nov 19, 2021: In an effort to prioritize Emergency Use Authorizations (EUA), the FDA does not recommend that BioPorto pursue an EUA for its NGAL assay for the prediction of renal replacement therapy in COVID-19 patients
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: BioPorto Diagnostics AS Pipeline Products and Ongoing Clinical Trials Overview
Table 2: BioPorto Diagnostics AS Pipeline Products by Equipment Type
Table 3: BioPorto Diagnostics AS Pipeline Products by Indication
Table 4: BioPorto Diagnostics AS, Key Facts
Table 5: BioPorto Diagnostics AS, Major Products and Services
Table 6: BioPorto Diagnostics AS Number of Pipeline Products by Development Stage
Table 7: BioPorto Diagnostics AS Pipeline Products Summary by Development Stage
Table 8: BioPorto Diagnostics AS Ongoing Clinical Trials by Trial Status
Table 9: BioPorto Diagnostics AS Ongoing Clinical Trials Summary
Table 10: gRAD Test - COVID-19 IgG/IgM - Product Status
Table 11: gRAD Test - COVID-19 IgG/IgM - Product Description
Table 12: gRAD Test - Sepsis - Product Status
Table 13: gRAD Test - Sepsis - Product Description
Table 14: NGAL (Neutrophil Gelatinase-Associated Lipocalin) Test - Kidney Injury - Product Status
Table 15: NGAL (Neutrophil Gelatinase-Associated Lipocalin) Test - Kidney Injury - Product Description
Table 16: Point of Care Test - SARS-CoV-2 - Product Status
Table 17: Point of Care Test - SARS-CoV-2 - Product Description
Table 18: ProNephro AKI (NGAL) - Pediatrics - Product Status
Table 19: ProNephro AKI (NGAL) - Pediatrics - Product Description
Table 20: ProNephro AKI (NGAL) - Pediatrics - Retrospective Clinical Pediatric NGAL Study Regarding Risk Use with Acute Kidney Injury (AKI): A Pivotal Clinical Study
Table 21: ProNephro AKI (NGAL) - Pediatrics - Study Verifying and Validating the Clinical Performance of NGAL Test for the Risk Assessment of Moderate to Severe Acute Kidney Injury (AKI) in Critically Ill Children
Table 22: The NGAL Test - Adults - Product Status
Table 23: The NGAL Test - Adults - Product Description
Table 24: BioPorto Diagnostics AS, Key Employees
Table 25: Glossary
List of Figures
Figure 1: BioPorto Diagnostics AS Pipeline Products by Equipment Type
Figure 2: BioPorto Diagnostics AS Pipeline Products by Development Stage
Figure 3: BioPorto Diagnostics AS Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings